Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 2/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | PTPN4 | P29074 | 2/20 | 0.34 |
| ▸ | PTPN9 | P43378 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604389 | 0.93 | TACR3 (0.39) | ACP3CTSGCETP | |
| SCHEMBL7609396 | 0.92 | CETP (0.40) | ACP3CTSGCETP | |
| SCHEMBL7604547 | 0.91 | ACP3 (0.40) | ACP3CTSGPPARGKDM4EALDH1A1 | |
| SCHEMBL7610424 | 0.84 | CTSG (0.43) | ACP3CTSGCMA1PTPN2PTPN1 | |
| SCHEMBL7610445 | 0.82 | PPARG (0.41) | PPARGPPARAALDH1A1CETP | |
| SCHEMBL7614365 | 0.76 | KMT2A (0.41) | ACP3CTSGKDM4EALDH1A1PTPN2 | |
| SCHEMBL7607401 | 0.75 | CNR2 (0.40) | PPARGPPARACETP | |
| SCHEMBL7609846 | 0.74 | CNR2 (0.41) | PPARGPPARACETP | |
| SCHEMBL5638282 | 0.74 | CYP2C9 (0.46) | ACP3PPARGPPARAALDH1A1CMA1 | |
| SCHEMBL7611820 | 0.74 | MMP1 (0.35) | KDM4EALDH1A1HSD17B10CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |